Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

James Sabry

Ronald Vale

James Spudich

Lawrence Goldstein

Cytokinetics, Incorporated

Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, enabling them to live their lives more fully.

Jazz Pharmaceuticals

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility. 

Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.

Royalty Pharma

Deerfield

Red Abbey Venture Partners

Federated Kaufmann Fund

International BM Biomedicine Holdings AG

New Medical Technologies

Duke University

Sevin Rosen Funds

Mayfield Fund

Vulcan

Cytokinetics

CYTK Investors: Today we announced we will be presenting at the upcoming Oppenheimer & Co. Inc. investor conference on February 13, 2024. 

Today we recognize #WearRedDay to spread awareness for women's heart health. Cardiovascular disease is the leading cause of death for women, killing more women than all forms of cancer combined and impacting women of all ages. Yet, many women don’t know that heart disease is their number one killer, made even worse by the fact that certain heart diseases can be “silent” or not diagnosed. Together, by wearing red, we are showing our support for heart disease prevention and bringing attention to the importance of heart health. #HeartMonth #HeartDiseaseAwareness #OurHearts #GoRedForWomen

To celebrate #BlackHistoryMonth, we're honoring the rich tapestry of African American culture and heritage that has shaped our world. This month is not just about the past, it's a call to action for the present and future. Let's learn, engage and uplift one another as we continue to build a world that celebrates diversity.

Learn more about the significance of this annual observance: https://bit.ly/3gptsgl

February is #HeartMonth! Follow along as we talk about #HeartDisease and connect with the community. Throughout the month, we will also be hosting internal company events to raise awareness and learn from patients about the burden of living with heart disease. #HCM

Today we announced the recipients of our sixth annual Cytokinetics Communications Grant Program. We are proud to support advocacy organizations in their efforts to build awareness and community engagement. 

Learn more:

Metric
Company Name	Cytokinetics, Incorporated	Jazz Pharmaceuticals
Symbol	CYTK
MSH ID	COM:CYTOKINETICS	COM:JAZZPHARMACEUTICALS
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals
Country	US	US
Stage	Post-IPO Debt
Employee Count	423
Website	cytokinetics.com	jazzpharmaceuticals.com
LinkedIn	cytokinetics
Founders

Metric
Market Cap	6.30B
Enterprise Value
Monthly Web Traffic	7.69K
Web Traffic Growth	0.64
Valuation
Raised Capital	50M

Metric
Revenue	7.53M
Revenue (LTM)
Revenue (NTM)
Gross Profit	-4.36M
EBITDA	-484.31M
Operating Income	-496.20M
Net Income	-526.24M
EPS	-5.45
Diluted EPS	-5.45
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-28.87
Operating Profit Margin	-65.90
EBITDA Margin	-64.32
Net Profit Margin	-69.64
Return on Equity	1.96
Return on Assets	-0.36
Return on Capital Employed	-0.36

COM:CYTOKINETICS

Cytokinetics, Incorporated

Last Close

47.67

22/11 21:00

Market Cap

6.30B

Beta: -

Volume Today

1.44M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-14.85
P/B Ratio	-17.56
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.15K
EV Multiple	-9.29

Metric
Days Sales Outstanding	116.72
Days Payables Outstanding	15.73
Days Inventory Outstanding
Operating Cycle	79.39
Cash Conversion Cycle	52.25
Asset Turnover	0.01

Metric
Operating Cash Flow	-414.33M
Free Cash Flow	-415.75M
Cash Flow to Debt	-0.59
Operating Cash Flow/Sales	-55.02
Free Cash Flow Yield	-0.04

Metric
Cash & Equivalents	113.40M
Accounts Receivable	-1.14M
Inventory
Goodwill
Debt to Capitalization	2.65
Debt to Assets	1.01
Current Ratio	7.22
Quick Ratio	10.39

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	6.06
R&D to Revenue	1.27
SG&A to Revenue	23.48